Loading...
•
Dec 31, 2020
Amneal Q4 2020 Earnings Report
Amneal's financial performance was reported for Q4 2020, with net revenue increasing and a net loss decreasing compared to the previous year.
Key Takeaways
Amneal Pharmaceuticals reported a 28% increase in net revenue to $510 million for Q4 2020. The company experienced a net loss of $3 million, an improvement from the $32 million loss in the same quarter of the previous year. Adjusted diluted EPS was $0.14, compared to $0.08 in the prior year.
Net revenue increased by 28% to $510 million compared to Q4 2019.
GAAP net loss improved to $3 million from a $32 million loss in the prior year.
Adjusted EBITDA increased by 33% to $107 million.
Adjusted diluted EPS increased to $0.14 from $0.08 in the prior year.
Revenue by Segment
Forward Guidance
Amneal provided its full year 2021 financial guidance, with net revenue expected to be between $2.1 billion and $2.2 billion and adjusted diluted EPS between $0.70 and $0.85.
Positive Outlook
- Net revenue between $2.1 billion - $2.2 billion
- Adjusted EBITDA between $500 million - $540 million
- Adjusted diluted EPS between $0.70 - $0.85
- Operating cash flow between $220 million - $250 million
- Capital expenditures between $60 million - $70 million
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...